CN107334778B - Purposes of the lycium ruthenicum polysaccharide in preparation treatment gout product - Google Patents
Purposes of the lycium ruthenicum polysaccharide in preparation treatment gout product Download PDFInfo
- Publication number
- CN107334778B CN107334778B CN201710686420.3A CN201710686420A CN107334778B CN 107334778 B CN107334778 B CN 107334778B CN 201710686420 A CN201710686420 A CN 201710686420A CN 107334778 B CN107334778 B CN 107334778B
- Authority
- CN
- China
- Prior art keywords
- drug
- lycium ruthenicum
- purposes
- gout
- polysaccharide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 201000005569 Gout Diseases 0.000 title claims abstract description 31
- 150000004676 glycans Chemical class 0.000 title claims abstract description 31
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 31
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 31
- 241000169546 Lycium ruthenicum Species 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 32
- 229940079593 drug Drugs 0.000 claims abstract description 27
- 230000002265 prevention Effects 0.000 claims abstract description 7
- 102000004889 Interleukin-6 Human genes 0.000 claims description 12
- 108090001005 Interleukin-6 Proteins 0.000 claims description 12
- 229940100601 interleukin-6 Drugs 0.000 claims description 12
- 235000013399 edible fruits Nutrition 0.000 claims description 8
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims description 7
- 230000001154 acute effect Effects 0.000 claims description 7
- 210000004369 blood Anatomy 0.000 claims description 7
- 239000008280 blood Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 4
- 108010074051 C-Reactive Protein Proteins 0.000 claims description 3
- 102000010906 Cyclooxygenase 1 Human genes 0.000 claims description 3
- 108010037464 Cyclooxygenase 1 Proteins 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 239000013078 crystal Substances 0.000 claims description 2
- 238000001556 precipitation Methods 0.000 claims description 2
- 238000003809 water extraction Methods 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- 239000010836 blood and blood product Substances 0.000 claims 1
- 229940125691 blood product Drugs 0.000 claims 1
- 235000013305 food Nutrition 0.000 abstract description 12
- 230000036541 health Effects 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 7
- 206010061218 Inflammation Diseases 0.000 abstract description 5
- 230000004054 inflammatory process Effects 0.000 abstract description 5
- 230000006870 function Effects 0.000 abstract description 4
- 238000011160 research Methods 0.000 abstract description 4
- 239000000047 product Substances 0.000 description 16
- 238000005259 measurement Methods 0.000 description 13
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 201000001431 Hyperuricemia Diseases 0.000 description 7
- 210000002683 foot Anatomy 0.000 description 7
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 5
- 206010003246 arthritis Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 229960000905 indomethacin Drugs 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000208292 Solanaceae Species 0.000 description 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 235000021028 berry Nutrition 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000002224 dissection Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 210000000548 hind-foot Anatomy 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 229940116269 uric acid Drugs 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 206010070968 Disorders of purine metabolism Diseases 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 241001106041 Lycium Species 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000005485 Thrombocytosis Diseases 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000026816 acute arthritis Diseases 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229960002708 antigout preparations Drugs 0.000 description 1
- 239000003150 biochemical marker Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000003284 horn Anatomy 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- NAFSTSRULRIERK-UHFFFAOYSA-M monosodium urate Chemical compound [Na+].N1C([O-])=NC(=O)C2=C1NC(=O)N2 NAFSTSRULRIERK-UHFFFAOYSA-M 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000012372 quality testing Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The present invention provides purposes of the lycium ruthenicum polysaccharide in the food, drug or health care product of preparation treatment gout.The research of the invention finds that can effectively prevent or treat gout caused by MSU using lycium ruthenicum polysaccharide, there is good functions of detumescence, relieving inflammation effect, provide new product for clinical prevention or/and treatment gout.
Description
Technical field
The present invention relates to the new applications of lycium ruthenicum polysaccharide.
Background technique
Gout (gout) is that long-term disorders of purine metabolism, blood uric acid increase one group of different substantiality disease for causing tissue damage.
Clinical characters be hyperuricemia (hyperuricemia, HUA), gouty acute arthritis recurrent exerbation, tophaceous deposition,
Characteristic chornic arthritis and joint deformity often involve kidney and arteriosclerotic kidney and kidney calculus urate are caused to be formed.Gout
Biochemical marker be hyperuricemia, refer to the lithate of extracellular fluid in over-saturation state.Lithate (monosodium urate
Crystal, MSU) it is deposited in crystalline form so as to cause a series of acute inflammatory reactions, as in joint and periarticular tissue
Gout.It is generally acknowledged that Xue Niao Suan≤416 μm ol/L is hyperuricemia, and the Patients with Hyperuricemia of about 5%-12% can develop
As gout, serum uric acid level continues have the chance of 70%-90% to obtain gout in 540 μm of ol/L persons.
It counting according to " Chinese medicinal application detection ", Patients with Hyperuricemia number in China's is up to 1.2 hundred million at present, and by high lithemia
The disease rates that mass formed by blood stasis evolves into gout are about 1/10.China's gout number of the infected is in 2015 up to 75,000,000, and gout is sent out
For sick rate every year also with 7.5% speed substantial increase, 1/5 gout patients have lost viability, the gout patients course of disease
More than 10 years, Yi Yinfa was difficult to the uremia cured, and heavy psychological pressure and financial burden are brought to patient and family.It is high
Uricacidemia and the diseases such as primary gout and obesity, hyperlipidemia, high blood pressure, diabetes, coronary heart disease are in significant positive
It closes.Therefore, gout is a kind of serious metabolic disease for endangering human health especially as diabetes.
For the treatment of acute stage gout, clinical medicine mainly select non-steroid anti-inflammatory drug (NASIDs), colchicin,
Cortex hormone of aadrenaline and antalgesic these four drugs.However, although these drug anti-inflammatory analgetics act on fast, medical expense
Height, and most drugs toxic side effect is quite obvious.
Black fruit fructus lycii (Lyciumruthenicum Murray) is the perennial shrub of Solanaceae (Solanaceae) Lycium
Low-temperature dark dries berry, black fruit fructus lycii is sweet in flavor, the mild-natured, heat that clears away heart-fire, for treating cardiopyretic disease, heart disease, irregular menstruation, menopause
Etc. illnesss.Black fruit fructus lycii is widely used as common edible berry or health food at present, and still, yet there are no will be black
Fruit fructus lycii or its extract are used to treat the research report of gout.
Summary of the invention
Based on above-mentioned status, the quasi- medical usage for providing lycium ruthenicum polysaccharide in terms of gout of the present invention.
Specifically, the present invention provides lycium ruthenicum polysaccharides in preparation prevention or/and food, drug or the guarantor for the treatment of gout
Purposes in strong product.
Further, the food, drug or health care product are food, drug or the guarantor of prevention or/and treatment acute gout
Strong product.
Gout of the present invention includes at least acute attack arthritis, tophus is formed, tophaceous chornic arthritis
Deng.
Further, the food, drug or health care product are anti-inflammatory food, drug or health care product.
Further, the food, drug or health care product are food, drug or the health care for reducing or removing urate crystal
Product.
Wherein, the food, drug or health care product are to reduce hs-CRP in blood, tumor necrosis factor α, white
Food, drug or the health care product of the content of at least one of interleukin -6, cyclooxygenase 1, prostaglandin E.
Wherein, it was unexpectedly observed that the function and effect of lycium ruthenicum polysaccharide are almost in the influence to inflammatory factor in experiment
All it is not so good as positive control medicine Indomethacin；But the reduction of interleukin-6 is acted on, the effect under lycium ruthenicum polysaccharide high dose
Fruit is significantly better than Indomethacin, and it is positive right that this illustrates that lycium ruthenicum polysaccharide will be substantially better than in the inhibiting effect to interleukin-6
According to drug.
Interleukin-6, abbreviation interleukin 6 (IL-6) are a kind of cell factors, belong to one kind of interleukins.It
It is by fibroblast, Monocytes/Macrophages, T lymphocyte, bone-marrow-derived lymphocyte, epithelial cell, horn cell and a variety of tumors
Produced by cell.IL-1, TNF-a, PDGF, virus infection, double-stranded RNA and c AMP etc. can induce normal cell and generate white Jie
Element 6.Interleukin 6 can stimulate the cell Proliferation for participating in being immunoreacted, differentiation and improve its function.It has now been discovered that Bai Jie
The abnormal of element 6 increases, and often has close association with multiple physical body disease, as thrombocythemia, diseases associated with inflammation, immune response are different
Often, osteoporosis, chronic joint rheumatism, hypercalcemia, Huppert's disease, cachexia, ephritis etc., it can participate in inflammatory reaction
And exothermic reaction.Therefore, based on the present invention to lycium ruthenicum polysaccharide to the significant inhibiting effect of interleukin-6, the present invention also provides
Lycium ruthenicum polysaccharide is preparing the purposes in interleukin-6 inhibitor.
Further, the present invention can use lycium ruthenicum polysaccharide treatment and increase extremely with interleukin-6 or abnormal activation phase
The disease of pass.
The present invention also provides lycium ruthenicum polysaccharides to prepare the purposes in tumor necrosis factor alpha inhibitors.
The research of the invention finds that can effectively prevent or treat gout caused by MSU using lycium ruthenicum polysaccharide, have good
Good functions of detumescence, relieving inflammation effect provides new product for clinical prevention or/and treatment gout.
According to general knowledge known in this field, plant extracts active component refer to the contents of the constituents 50% or more,
Such as the content of polysaccharide should reach 50% or more in polysaccharide position.In lycium ruthenicum polysaccharide of the present invention, polysaccharide component contains
Amount should also be maintained at 50% or more.In a specific embodiment of the invention, polyoses content prepared by the present invention is about 65~
75%, such as 65%, 70%, 75% etc..
Wherein, the lycium ruthenicum polysaccharide is to be prepared using black fruit fructus lycii as raw material by water extraction and alcohol precipitation method.
Based on above-mentioned discovery, the present invention also provides the products containing lycium ruthenicum polysaccharide in preparation prevention or/and treatment
Purposes in the food of gout, drug or health care product.
Active constituent in above-mentioned " product " includes at least lycium ruthenicum polysaccharide one kind, it is of course also possible to only with black
Fruit polysaccharides is active constituent.In addition, can also include relevant auxiliary material or complementary ingredient in the product.
The product is given by gastrointestinal tract absorption features, can prepare different preparation types according to actual needs,
Such as liquid form, solid form.Based on different preparation types, different auxiliary materials can choose.
Detailed description of the invention
Fig. 1 rat paw edema measurement result, wherein G1=low dose group, G2=middle dose group, G3=high dose group, with
Blank group is that reference group does variance analysis, P** < 0.01 be it is extremely significant, p* < 0.05 is significant；
Specific embodiment
The present invention is further elaborated combined with specific embodiments below, but the present invention does not limit to and following embodiment,
The raw material can obtain unless otherwise specified from public commercial source.
1. sample preparation
Lycium ruthenicum polysaccharide crude extract: smash it through 80 DEG C of 20 mesh screens → distilled water extract three times → recycling filtrate →
3000r10min centrifugation → supernatant → 70 degree Celsius spin concentration → addition edible alcohol (97%) → taking precipitate → by text
Method removing protein is offered, purifying → vacuum drying is for 24 hours
After measured, the resulting polysaccharides purity of the present invention is 70%.
2. experimental animal
Rat: SD kind, SPF grades of 180-200g, male sell unit: Hunan SJA Laboratory Animal Co. , Ltd,
Quality testing unit: Hunan SJA Laboratory Animal Co. , Ltd sells unit credit number: SCXK (Hunan) 2013-
0004, experimental unit's licensing number: SYXK (blueness) 2012-0001
3. rat acute Gout Model pharmacological research experimental method
Animal packet: adaptive feeding one week after grouping is divided into 6 groups, each group 10, is respectively as follows: blank group, model group,
Positive drug group, the low middle high dose group of test specimen are 3 groups, amount to 6 groups
Lycium ruthenicum polysaccharide crude extract is formulated as 8g/100ml with sterilized water for injection, and low middle high dose group is respectively
100mg/kg, 200mg/kg, 400mg/kg fill 0.25ml, 0.5ml, 1ml respectively.Before measurement, per average daily administration, positive drug
Object is identical.
Acute gout inducer MSU: it is formulated as 40mg/ml, and ultrasound 10min with 0.9%NaCl, in Rat Right foot foot pad
Intracutaneous injection 0.1ml
Positive drug: being formulated as 50mg/100ml for Indomethacin with 0.9%NaCl, is administered by 3mg/kg, fills 1.2ml,
Use preceding ultrasound 10min
Foot swelling measurement: every group of right hind foot of rat thickness is measured with electronic vernier caliper by a people respectively, is measured respectively
0h, 4h, for 24 hours, the right metapedes thickness after 48h, 72h
Exoculation pearl takes blood and the execution that dislocates after observation 72h, and 12h is deprived of food but not water before putting to death, and liver, spleen, kidney, the right side are taken after dissection
Metapedes
Blood: 2000r takes supernatant 3000r centrifugation 5min that serum is taken to be put into -80 after being centrifuged 5min after taking blood to be placed at room temperature for 2h
DEG C spare of refrigerator
Liver, spleen, kidney, right metapedes: dissection takes liver, spleen, kidney, and right metapedes uses yarn after physiological saline Rapid Cleaning two times
Cloth water suction, is put into valve bag after weighing, is put into the spare of -80 DEG C of refrigerators
4 test results
4.1 foot swelling measurement results
Data are with 10 rat paw edemas in Fig. 1Variance analysis is carried out with one-way anova.By scheming
Known to us: 0h each group right hind foot of rat measurement result illustrates that the right metapedes thickness of each group mouse is almost the same, 4h without significant difference
The right metapedes thickness of measurement result display model group significantly increases and changes less in 72 afterwards, illustrates our modeling successes；4h
Just there is foot swelling significant decrease, middle dose group and high dose group and foot swelling occurs in 72h significantly dropping in the right metapedes of positive drug afterwards
It is low, primarily determine that middle dose group and high dose group have conspicuousness effect, and little by scheming high dose group difference in known.
4.2 inflammatory factors evaluate antigout effect
1 inflammatory factor measurement result of table
Note: doing variance analysis using model group as reference group, P** < 0.01 be it is extremely significant, p* < 0.05 is significant；With positive drug
Object is control, p# < 0.05
Data are measured with 10 rat blood serums in upper tableVariance analysis is carried out with one-way anova.
By upper table result it is found that the measurement result of hs-CRP show in high dose group have compared with model group
Significant difference, and middle high dose group difference is little；The measurement result of tumor necrosis factor a shows low middle high dose group and model
Group more all has significant difference, and reduces at dosage correlation, but the difference between middle high dose group is far smaller than in low
Difference between dosage；The measurement result of interleukin-6 show in high dose group compared with model group all have conspicuousness it is poor
It is different, and middle high dose group difference is little；The measurement result of cyclooxygenase 1 show in high dose group all have compared with model group it is aobvious
Sex differernce is write, and the difference between low middle dosage is much higher than the difference between middle high dose；The measurement result of prostaglandin E is shown
Middle high dose group all has significant difference compared with model group, and middle high dose group difference is little.Biochemical indicator in summary
Measurement result analysis is it is found that optimal dose group is middle dose group, that is, 0.2g/kg.
The above is only the preferred embodiment of the present invention, it is noted that above-mentioned preferred embodiment is not construed as pair
Limitation of the invention, protection scope of the present invention should be defined by the scope defined by the claims..For the art
For those of ordinary skill, without departing from the spirit and scope of the present invention, several improvements and modifications can also be made, these change
It also should be regarded as protection scope of the present invention into retouching.
Claims (8)
1. purposes of the lycium ruthenicum polysaccharide in the drug of preparation prevention or/and treatment gout, more in the lycium ruthenicum polysaccharide
Sugared content is 50% or more.
2. purposes according to claim 1, it is characterised in that: the drug is the medicine of prevention or/and treatment acute gout
Product.
3. purposes according to claim 1, it is characterised in that: the drug is anti-inflammatory drug.
4. purposes according to claim 1, it is characterised in that: the drug is to reduce hs-CRP, tumour in blood
The drug of the content of at least one of necrosin &, cyclooxygenase 1, prostaglandin E.
5. purposes according to claim 1, it is characterised in that: the drug is the medicine for reducing interleukin-6 content in blood
Product.
6. purposes according to claim 1, it is characterised in that: the drug is the medicine for reducing or removing urate crystal
Product.
7. purposes described in claim 1~6 any one, it is characterised in that: polyoses content is in the lycium ruthenicum polysaccharide
65~75%.
8. purposes described in any one according to claim 1~6, it is characterised in that: polysaccharide is in the lycium ruthenicum polysaccharide
Using black fruit fructus lycii as raw material, it is prepared by water extraction and alcohol precipitation method.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710686420.3A CN107334778B (en) | 2017-08-11 | 2017-08-11 | Purposes of the lycium ruthenicum polysaccharide in preparation treatment gout product |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710686420.3A CN107334778B (en) | 2017-08-11 | 2017-08-11 | Purposes of the lycium ruthenicum polysaccharide in preparation treatment gout product |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107334778A CN107334778A (en) | 2017-11-10 |
| CN107334778B true CN107334778B (en) | 2019-03-29 |
Family
ID=60216864
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710686420.3A Active CN107334778B (en) | 2017-08-11 | 2017-08-11 | Purposes of the lycium ruthenicum polysaccharide in preparation treatment gout product |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107334778B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114052110A (en) * | 2022-01-17 | 2022-02-18 | 首都医科大学附属北京友谊医院 | Combined natural food tea substitute beverage and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105053417A (en) * | 2015-09-06 | 2015-11-18 | 青海之也科技咨询服务有限公司 | Lycium ruthenicum Murr tea drink and preparation method thereof |
| CN106962551A (en) * | 2017-03-19 | 2017-07-21 | 贵阳中医学院第二附属医院 | A kind of tea-drinking for gout |
-
2017
- 2017-08-11 CN CN201710686420.3A patent/CN107334778B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105053417A (en) * | 2015-09-06 | 2015-11-18 | 青海之也科技咨询服务有限公司 | Lycium ruthenicum Murr tea drink and preparation method thereof |
| CN106962551A (en) * | 2017-03-19 | 2017-07-21 | 贵阳中医学院第二附属医院 | A kind of tea-drinking for gout |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107334778A (en) | 2017-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200506723B (en) | Composition for treating hepatitis C | |
| CN103933224B (en) | A kind of Chinese medicine composition for treating gout | |
| CN107334778B (en) | Purposes of the lycium ruthenicum polysaccharide in preparation treatment gout product | |
| CN101773580A (en) | Traditional Chinese medicine composition for curing infantile acute bronchitis and preparation method | |
| CN101406688A (en) | Compound formulation for treating rheumatic arthritis and rheumatoid arthritis | |
| CN107281323A (en) | Purposes of the black fruit fructus lycii powder in anti-trioxypurine or treatment gout product is prepared | |
| CN107375532A (en) | Black fruit fructus lycii extract is preparing the purposes in treating gout product | |
| WO2021169682A1 (en) | Traditional chinese medicine composition, and preparation method therefor and application thereof | |
| CN111375035B (en) | Preparation and application of enteric-coated preparation for treating cervical spondylosis | |
| CN109481469A (en) | Application of the drug and colla carapacis et plastri testudinis of a kind of colla carapacis et plastri testudinis treatment gout in preparation treatment gout drug | |
| CN107496437B (en) | Black fruit fructus lycii is preparing the purposes in anti-trioxypurine product | |
| CN102488825B (en) | Traditional Chinese medicine composition for treating beriberoid pyretic arthralgia and application of traditional Chinese medicine composition | |
| CN104940813A (en) | Traditional Chinese medicine composition for treating cholelithiasis and cholecystitis, and preparation method thereof | |
| CN107468816A (en) | A kind of pharmaceutical composition for treating gout | |
| CN109692203A (en) | A kind of pharmaceutical composition with antigout effect | |
| CN107467568A (en) | A kind of natural composition for preventing or treating gout and application thereof | |
| CN104491316B (en) | A kind of Chinese medicine preparation for the treatment of deficiency of QI in middle-JIAO type hyperplasia of prostate | |
| CN104257779B (en) | Gout-resisting pharmaceutical composition and preparation method of gout-resisting pharmaceutical composition | |
| CN113101331B (en) | Thyme herb tea and preparation method and application thereof | |
| CN102552767A (en) | Traditional Chinese medicine for treating kidney stone, preparation method and administration mode | |
| CN105106773B (en) | A kind of Chinese medicine composition for treating gout | |
| CN105902619B (en) | A kind of Chinese medicine composition and preparation method thereof for treating I type dengue virus infection | |
| CN105106497B (en) | A kind of Chinese medicine and preparation method thereof treated hyperuricemia and merge dyslipidemia | |
| CN104983799A (en) | Traditional Chinese medicine composition for treating pulmonary abscess in abscess formation stage | |
| CN107233540A (en) | A kind of Chinese medicine composition for treating rheumatoid arthritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |